Moderna Inc. (MRNA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Moderna Inc. (MRNA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

34.47

-0.68 (-1.93%)

At close: Jan 14, 2025, 3:59 PM

34.10

-1.06%

Pre-market Jan 15, 2025, 06:41 AM EST

undefined% (undefined)

Bid	34.05
Market Cap	13.26B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.81
PE Ratio (ttm)	-5.93
Forward PE	n/a
Analyst	Hold

Ask	34.35
Volume	12,361,151
Avg. Volume (20D)	8,716,724
Open	35.10
Previous Close	35.15
Day's Range	33.18 - 35.68
52-Week Range	31.94 - 170.47
Beta	undefined

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 7, 2018

Employees 5,600

Stock Exchange NASDAQ

Ticker Symbol MRNA

Website https://www.modernatx.com

Analyst Forecast

According to 18 analyst ratings, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $69, which is an increase of 100.20% from the latest price.

Buy 27.78%

Hold 55.56%

Sell 16.67%

Stock Forecasts

Next Earnings Release

Moderna Inc. is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of $1.57B, reflecting a -44.15% YoY shrinking and earnings per share of -1.46, making a -365.45% decrease YoY.

Why Price Moved

2 days ago · Source

-16.8%

Moderna shares are trading lower after the company... Unlock content with Pro Subscription

1 week ago · Source

-9.17%

Moderna shares are trading lower after UBS cut its price target on the stock from $108 to $96.

News

1 day ago · zacks.com

Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Moderna (MRNA) settling at $34.45, representing a -1.98% change from its previous close.

1 day ago · zacks.com

Moderna Stock Plummets 17% on 2025 Sales Guidance Slash

The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.

1 day ago · newsfilecorp.com

ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company ...

2 days ago · investopedia.com

Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook

Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion.

2 days ago · seekingalpha.com

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

1 day ago · investopedia.com

S&P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast

Major U.S. equities indexes were mixed to start a new trading week ahead of inflation data that could provide some clarity on the interest-rate outlook for 2025. Earnings reports from the largest U.S....

1 day ago · proactiveinvestors.com

Moderna slashes 2025 sales forecast, shares sink

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plunged almost 20% after the drugmaker pre-announced fiscal 2024 sales below expectations. The company expects sales of $3 billion to $3.1 billion, below the ...

1 day ago · invezz.com

S&P 500, Nasdaq slip as key tech stocks fall; US Steel shares jump, Moderna stock tanks

US stocks saw a decline on Monday as investors continued to unload key tech shares that have been driving the bull market. The S&P 500 fell by 0.2%, while the Nasdaq Composite dropped 0.8%.

1 day ago · investopedia.com

Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%

Shares of pharmaceutical giant Moderna (MRNA) plunged Monday after the company cut its 2025 revenue forecast by $1 billion.

1 day ago · fool.com

Why Moderna Stock Just Crashed 21%

Moderna's (MRNA -21.95%) sales are slowing down, and Moderna stock is going down -- a lot.

2 days ago · schaeffersresearch.com

Moderna Stock Heads for Worst-Ever Day After Reducing Revenue Forecast

Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates.

2 days ago · schaeffersresearch.com

Moderna Stock Heads for Worst Day Ever on Forecast Cut

Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates.

2 days ago · youtube.com

Cramer's Stop Trading: Moderna

CNBC's Jim Cramer explains why he is keeping an eye on shares of Moderna.

2 days ago · investors.com

Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance

Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting initiative. The post Moderna Stock Crashes 21% After Covid Vaccine Maker Slas...

2 days ago · youtube.com

TSLA Bull's A.I. Thesis, LULU Ups Guidance & MRNA Plunges

Morgan Stanley raised its price target on Tesla (TSLA) with optimism behind the company's A.I. and autonomous driving expectations.

2 days ago · benzinga.com

Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives

Moderna Inc. MRNA stock plunged on Monday after the company announced business updates and progress across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing ...

2 days ago · cnbc.com

Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion

Moderna lowered its 2025 sales guidance by roughly $1 billion, as it continues to cut costs. The biotech company now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of whi...

2 days ago · marketwatch.com

Moderna's stock tumbles to post-COVID lows after revenue outlook disappoints

Moderna's stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.

2 days ago · barrons.com

Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.

The company said Monday that it expects 2025 revenue of between $1.5 billion and $2.5 billion.

2 days ago · reuters.com

Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines.

Load More News